EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)VergleichsstudieRandomisierte kontrollierte Studie

Phase 3 Trial of Selpercatinib in Advanced RET -Mutant Medullary Thyroid Cancer

Julien Hadoux, Rossella Elisei, Marcia S Brose, Ana O Hoff, Bruce G Robinson, Ming Gao, Barbara Jarzab, Pavel Isaev, Katerina Kopeckova, Jonathan Wadsley, Dagmar Führer, Bhumsuk Keam und 13 weitere

New England Journal of Medicine · 16.11.2023 · 389 (20) · 1851-1861

DOI: 10.1056/nejmoa2309719 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift New England Journal of Medicine, erschienen am 16.11.2023. Verfasst von Julien Hadoux und 24 weiteren Autor:innen. Beteiligte Einrichtung: From the Service d'oncologie endocrinienne, département d'imagerie, Gustave Roussy and ENDOCAN-TUTHYREF Network, Villejuif (J.H.), and the Nuclear Me…. Hauptthemen laut MEDLINE: Pyridines, Antineoplastic Agents, Thyroid Neoplasms. Die Arbeit wurde bisher 221-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: Loxo Oncology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PyridinesAntineoplastic AgentsThyroid NeoplasmsDisease ProgressionQuinazolinesHumansPiperidinesProto-Oncogene Proteins c-retAnilidesPyrazolesCarcinoma, Neuroendocrine

Substanzen

PyridinesAntineoplastic AgentsQuinazolinesPiperidinesProto-Oncogene Proteins c-retcabozantinibAnilidesRET protein, humanselpercatinibPyrazoles

Autor:innen und Institutionen

  • From the Service d'oncologie endocrinienne, département d'imagerie, Gustave Roussy and ENDOCAN-TUTHYREF Network, Villejuif (J.H.), and the Nuclear Medicine Department and Thyroid Unit, Centre François Baclesse, Caen (S.…

ORCID-Profile: Ravinder Singh

Förderung

  • Loxo Oncology

Zitieren

APA

Hadoux, J., Elisei, R., Brose, M. S., Hoff, A. O., Robinson, B. G., Gao, M., Jarzab, B., Isaev, P., Kopeckova, K., Wadsley, J., Führer, D., Keam, B., Bardet, S., Sherman, E. J., Tahara, M., Hu, M. I., Singh, R., Lin, Y., Soldatenkova, V., …, & LIBRETTO-531 Trial Investigators (2023). Phase 3 Trial of Selpercatinib in Advanced RET -Mutant Medullary Thyroid Cancer. New England Journal of Medicine, 389(20), 1851-1861. https://doi.org/10.1056/nejmoa2309719

Vancouver

Hadoux J, Elisei R, Brose MS, Hoff AO, Robinson BG, Gao M, et al. Phase 3 Trial of Selpercatinib in Advanced RET -Mutant Medullary Thyroid Cancer. New England Journal of Medicine. 2023;389(20):1851-1861. doi:10.1056/nejmoa2309719

BibTeX
@article{Hadoux2023,
  author = {Hadoux, Julien and Elisei, Rossella and Brose, Marcia S and Hoff, Ana O and Robinson, Bruce G and Gao, Ming and Jarzab, Barbara and Isaev, Pavel and Kopeckova, Katerina and Wadsley, Jonathan and Führer, Dagmar and Keam, Bhumsuk and Bardet, Stéphane and Sherman, Eric J and Tahara, Makoto and Hu, Mimi I and Singh, Ravinder and Lin, Yan and Soldatenkova, Victoria and Wright, Jennifer and Lin, Boris and Maeda, Patricia and Capdevila, Jaume and Wirth, Lori J and LIBRETTO-531 Trial Investigators, LIBRETTO-531 Trial Investigators},
  title = {Phase 3 Trial of Selpercatinib in Advanced RET -Mutant Medullary Thyroid Cancer},
  journal = {New England Journal of Medicine},
  year = {2023},
  volume = {389},
  number = {20},
  pages = {1851--1861},
  doi = {10.1056/nejmoa2309719}
}
Kostenlos starten →